Balanced Growth in Pharmaceuticals, Overseas, and Healthcare Businesses
Expansion Expected in Overseas Business Based on Pharmaceutical Ingredients

Yuhan Corporation continued its sales growth in the first quarter of this year, but profitability appeared to decline slightly compared to the previous quarter.


Corporate logo image of Yuhan Corporation. Yuhan Corporation

Corporate logo image of Yuhan Corporation. Yuhan Corporation

View original image

On April 30, Yuhan Corporation announced through its regulatory filing that its standalone sales for the first quarter of 2026 reached 509.6 billion won, an increase of 8.6% from the same period last year. However, compared to the previous quarter, this figure decreased by 3.7%.


Operating profit totaled 8.8 billion won, increasing by only 2.1% year-on-year. Compared to the previous quarter, it plunged by 72.3%. Despite sales growth, the level of profit contracted significantly.


Profit from continuing operations before income tax came to 41.2 billion won, a decrease of 5.1% from the previous year. Net profit during the period also dropped by 5.0% to 37.4 billion won. Compared to the previous quarter, both figures fell by around 67%.


On a consolidated basis, the company posted sales of 526.8 billion won, operating profit of 8.8 billion won, and net profit of 23.3 billion won.


A Yuhan Corporation official commented, “In the first quarter, balanced growth in the pharmaceuticals, overseas, and healthcare businesses resulted in nearly 9% year-on-year sales growth on a standalone basis.” The official added, “In particular, the overseas business based on pharmaceutical ingredients continues to maintain a high growth rate, and the company will sustain its upward momentum by accelerating early achievements in research and development.”





This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing